CommercialCoverageMedium impact
Policy Criteria Change
Arkansas Blue Cross Blue Shield·AR · Oncology, Dermatology·Medical Policy
Effective date
May 15, 2026
We identified it
Jun 19, 2026
Summary
Arkansas Blue Cross updated multiple policies effective 5/15/2026. Key change: Signatera tumor-informed circulating tumor DNA testing (CPT 0340U) is now covered for newly diagnosed Merkel Cell Carcinoma patients. Several other policies including liver transplant criteria were updated, and 6 policies will be archived in April 2026.
Action Required
By May 15, 2026: Update billing system to allow coverage for CPT code 0340U (Signatera ctDNA testing) specifically for newly diagnosed Merkel Cell Carcinoma patients. Ensure documentation clearly indicates this diagnosis and that testing is for detecting molecular residual disease and guiding adjuvant management. All other ctDNA testing indications remain non-covered.